Leerink Partnrs Issues Positive Outlook for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a research note issued to investors on Monday, February 17th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of $0.77 for the quarter, up from their prior estimate of $0.70. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.18 EPS, FY2027 earnings at $8.85 EPS and FY2029 earnings at $9.00 EPS.

A number of other analysts have also commented on NBIX. HC Wainwright reiterated a “buy” rating and issued a $185.00 price objective on shares of Neurocrine Biosciences in a research report on Friday. Guggenheim decreased their target price on Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Piper Sandler restated an “overweight” rating and set a $160.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Morgan Stanley boosted their target price on Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Finally, StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $166.90.

Neurocrine Biosciences Stock Up 3.9 %

Shares of NBIX stock opened at $120.69 on Thursday. The stock has a 50-day moving average price of $136.75 and a 200 day moving average price of $129.71. The firm has a market cap of $12.03 billion, a price-to-earnings ratio of 36.68, a PEG ratio of 0.76 and a beta of 0.33. Neurocrine Biosciences has a 12 month low of $110.95 and a 12 month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

Neurocrine Biosciences announced that its board has authorized a share repurchase plan on Friday, February 21st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to repurchase up to 4.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its stock is undervalued.

Insider Transactions at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 1,283 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.87, for a total transaction of $196,132.21. Following the transaction, the chief financial officer now directly owns 32,681 shares of the company’s stock, valued at approximately $4,995,944.47. The trade was a 3.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 272 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total value of $37,563.20. Following the transaction, the insider now directly owns 2,507 shares in the company, valued at $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 236,600 shares of company stock worth $34,348,261 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Golden State Wealth Management LLC acquired a new position in Neurocrine Biosciences in the 4th quarter valued at $25,000. Huntington National Bank grew its holdings in Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock valued at $31,000 after buying an additional 97 shares in the last quarter. Brooklyn Investment Group grew its holdings in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 115 shares in the last quarter. GeoWealth Management LLC lifted its position in shares of Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock valued at $35,000 after acquiring an additional 102 shares during the period. Finally, Blue Trust Inc. lifted its position in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.